Literature DB >> 2318148

Changes in the hypothalamo-pituitary-adrenal axis of genetically obese fa/fa rats: a structural, immunocytochemical, and morphometrical study.

G E Bestetti1, F Abramo, C Guillaume-Gentil, F Rohner-Jeanrenaud, B Jeanrenaud, G L Rossi.   

Abstract

Most metabolic disorders of genetically obese Zucker rats are reversed by adrenalectomy and are restored by corticosterone treatment, thus suggesting that a functional hypercorticosteronemic state is involved in the pathogenesis of the obesity syndrome in fa/fa rats. However, the hormone content and morphology of the hypothalamo-pituitary-adrenal axis of this animal model have to our knowledge not yet been described. We, thus, investigated morphologically and morphometrically the hypothalamic regions involved in CRF synthesis and secretion in male fa/fa rats. To ascertain if the brain is selectively or uniformly affected, we studied the main nuclei of the lateral and mediobasal hypothalamus, i.e. arcuate, lateral hypothalamic, and ventromedial nucleus and the parvicellular portion of the paraventricular nucleus. Moreover, after immunocytochemical labeling, we analyzed densitometrically the CRF-bearing axons of the median eminence and the ACTH-containing cells of the anterior and intermediate lobe of the pituitary gland. Finally, we investigated the adrenal glands by qualitative light microscopy. In fa/fa rats most hypothalamic nuclei were structurally changed. Furthermore, hypothalamic CRF and anterior pituitary ACTH contents as well as adrenal weight were increased, the zona fasciculata of the adrenal cortex was hypertrophic, and the ACTH content of the intermediate lobe was reduced. In conclusion, our results demonstrate that the obesity syndrome in genetically obese fa/fa rats is associated with lesions of the hypothalamo-pituitary-adrenal axis consistent with hyperadrenocorticism due to hyperactivity of the whole adrenal axis. Alterations also occur in the hypothalamic nuclei controlling glycemia, insulinemia, and circadian corticosterone secretion.

Entities:  

Mesh:

Year:  1990        PMID: 2318148     DOI: 10.1210/endo-126-4-1880

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Diabetes increases the expression of hypothalamic neuropeptides in a spontaneous model of type I diabetes, the nonobese diabetic (NOD) mouse.

Authors:  F E Saravia; S L Gonzalez; P Roig; V Alves; F Homo-Delarche; A F De Nicola
Journal:  Cell Mol Neurobiol       Date:  2001-02       Impact factor: 5.046

2.  Cafeteria diet-induced obese rats have an increased somatostatin protein content and gene expression in the periventricular nucleus.

Authors:  X Zhou; J De Schepper; A Vergeylen; O Luis; M Delhase; E L Hooghe-Peters
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

Review 3.  Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint.

Authors:  B Jeanrenaud
Journal:  Diabetologia       Date:  1995-08       Impact factor: 10.122

4.  Impact of Adiposity and Fat Distribution on the Dynamics of Adrenocorticotropin and Cortisol Rhythms.

Authors:  Ferdinand Roelfsema; Alberto M Pereira; Johannes D Veldhuis
Journal:  Curr Obes Rep       Date:  2014-12

5.  Effect of adrenalectomy on the development of a pancreatic islet lesion in fa/fa rats.

Authors:  M T Kibenge; C B Chan
Journal:  Diabetologia       Date:  1996-02       Impact factor: 10.122

6.  Insulin Regulates Adrenal Steroidogenesis by Stabilizing SF-1 Activity.

Authors:  Ann W Kinyua; Khanh V Doan; Dong Joo Yang; My Khanh Q Huynh; Yun-Hee Choi; Dong Min Shin; Ki Woo Kim
Journal:  Sci Rep       Date:  2018-03-22       Impact factor: 4.379

7.  Insulin and obesity transform hypothalamic-pituitary-adrenal axis stemness and function in a hyperactive state.

Authors:  Martin Werdermann; Ilona Berger; Laura D Scriba; Alice Santambrogio; Pia Schlinkert; Heike Brendel; Henning Morawietz; Andreas Schedl; Mirko Peitzsch; Aileen J F King; Cynthia L Andoniadou; Stefan R Bornstein; Charlotte Steenblock
Journal:  Mol Metab       Date:  2020-11-04       Impact factor: 7.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.